Effective and safe examination of Luseogliflozin for patients with fatty liver merger type II diabetes mellitus

Trial Profile

Effective and safe examination of Luseogliflozin for patients with fatty liver merger type II diabetes mellitus

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Aug 2017

At a glance

  • Drugs Luseogliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 21 Feb 2017 Status changed from recruiting to active, no longer recruiting.
    • 06 Sep 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top